# Stelis Biopharma Private

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stelis-biopharma-private

- Industry: Biotechnology
- Headquarters: Bangalore, India
- Website: www.stelis.com
- Total disclosed funding: $85M
- Latest round: Series C (Mar 19, 2021)
- Investors on record: 4

## About

Stelis Biopharma Private Limited, based in India, is a contract development and manufacturing organization (CDMO) specializing in complex injectables, offering comprehensive pharmaceutical solutions to clients globally.Founded in 2012 in Bangalore, India, Stelis Biopharma Private Limited operates as a contract development and manufacturing organization focused on innovative pharmaceutical solutions. The company has raised a total of USD 85.00 mn over multiple funding rounds, with the latest funding being a SERIES B round of USD 40.00 mn on March 19, 2021, led by TPG, including participation from Mankekar Family Office, Route One Investment Company, and Think Investment Management. The company has undergone strategic pivots to enhance its service offerings in the competitive pharmaceutical landscape.Stelis Biopharma's OneSource offers multimodal specialty pharmaceutical services, including the development and manufacturing of complex injectables such as sterile liquids, lyophilized vials, prefilled syringes, and dry powder injections. The company also provides assembly solutions for drug-device combinations, ensuring high-quality production that meets diverse market demands and regulatory compliance across North America and Europe. OneSource primarily serves pharmaceutical companies seeking robust support in drug development and commercial manufacturing.In the most recent fiscal year 2023, Stelis Biopharma reported a revenue of USD 5.12 mn, with an EBITDA of USD -70.77 mn. The revenue model is primarily based on service contracts with pharmaceutical companies for drug development and manufacturing, emphasizing a B2B engagement structure that outlines specific project pricing.Stelis Biopharma aims to leverage its recent SERIES B funding, which raised USD 70.00 mn as part of a larger USD 195.00 mn equity financing, to fuel growth and scale operations. The company plans to introduce new products targeting emerging therapies and expand into markets in North America and Europe by 2025. The additional capital will support initiatives for new drug development and enhance manufacturing capabilities, ensuring operational excellence as they grow their market presence.

## Funding rounds

- Series C, Mar 19, 2021, $85M — TPG, Route One Investment Company, Think Investments, Mankekar Family Office

## Investors

- TPG (https://capitalatlas.ai/funds/tpg) — Series C
- Route One Investment Company — Series C
- Think Investments — Series C
- Mankekar Family Office — Series C